Therapeutic Advances in Endocrinology and Metabolism

Review
Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
Kira B. Harris and Delilah J. McCarty
Ther Adv Endocrinol Metab
2015, Vol. 6(1) 3 –18DOI: 10.1177/
2042018814558242© The Author(s), 2014. Reprints and permissions: doc.guandang.net journalsPermissions.nav
Abstract: Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2 diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists (RAs) are currently indicated for T2DM in the USA. Exenatide and liraglutide are short-acting and require twice-daily and daily dosing, respectively. Two longer acting agents, exenatide long-acting release (LAR) and albiglutide, were formulated to allow for once-weekly dosing. All four GLP-1 RAs have demonstrated reductions in hemoglobin A1c, fasting blood glucose, and body weight both as monotherapy and in combination with first- and second-line diabetes agents including metformin, sulfonylureas, thiazolidinediones, and insulin.
Greater glycemic control was seen with liraglutide compared with the other GLP-1 treatment options; however, the two long-acting agents were superior to exenatide twice daily. All agents were well tolerated with most adverse events being mild or moderate in nature. The most common adverse event was transient nausea which typically resolved 4–8 weeks after treatment initiation. Long-acting agents had lower rates of nausea but an increased incidence of injection site reactions. Trials have suggested GLP-1 RAs may improve cardiovascular risk factors including blood pressure, lipid parameters and inflammatory markers. Future trials are needed to confirm the clinical outcomes of these agents. Overall, GLP-1 RAs will provide benefit for patients with T2DM intolerable to or not reaching glycemic goals with first-line agents, especially in patients in need of weight loss.
Keywords: albiglutide, exenatide, exenatide long-acting release, GLP-1 RAs, liraglutide, type 2 diabetes mellitus
et al. 1999]. This glucose-dependent effect Correspondence to: Introduction
Kira B. Harris, PharmD,
Glucagon-like peptide 1 (GLP-1) is an endoge-reduces the risk of hypoglycemia.BCPS, CDE
Assistant Professor, nous hormone produced and released by intesti-Wingate University School
nal epithelial endocrine L cells in response to of Pharmacy, 515 North food intake [Holst, 2007; Frias and Edelman, The use of GLP-1 therapy was limited by its rapid Main Street, Wingate,
NC 28174, USA
2007; Nauck et al. 2004]. While the effects of breakdown by dipeptidyl peptidase IV (DPP-IV) k.brice@wingate.eduGLP-1, including increased insulin secretion, [Holst, 2006, 2007]. However, several GLP-1 Delilah J. McCarty, decreased glucagon secretion, slowed gastric receptor agonists have been discovered that are PharmD, CPP, BCACP,
CDE
emptying, and maintenance of blood glucose DPP-IV resistant, making them valuable in diabe-Wingate University School (BG) levels, are maintained, GLP-1 secretion is tes treatment. Exenatide and liraglutide were US of Pharmacy, Wingate,
NC, USA

often reduced in patients with type 2 diabetes Food and Drug Administration (FDA) approved mellitus (T2DM) [Holst, 2007; Frias and in 2005 and 2010 and are administered subcuta-Edelman, 2007; Nauck et al. 2004; Kreymann neously twice daily and daily, respectively [Amylin et al. 1987; Nauck et al. 1986]. When exogenous Pharmaceuticals, Inc., 2011; Novo Nordisk A/S, GLP-1 is administered to patients with T2DM, 2013]. In 2012 and 2014, exenatide long-acting fasting BG (FBG) is decreased while c-peptide release (LAR) and albiglutide were approved. and insulin secretion are increased until BG These agents were modified to increase the half returns to normal [Nauck et al. 1993; Toft-Nielsen life, allowing for once weekly subcutaneous
doc.guandang.net 3
2011,Vol.17 No.8 Issue No.235 doi:10.3969/j.issn.1009-4393.2011.8.014 GLP-1及其类似物的研究进展李国慧 高如攀 综述 Summarize 多数2型糖尿病患者...
Chinese Journal of New Drugs 2013 , 22 ( 5 ) ·综述· GLP1 类似物在 2 型糖尿病中的临床应用进展 1, 2 1, 3 1 1 宋智慧 ,王璐, 纪立伟 ,胡...
180 糖尿病天地?临床刊 2012年4月 第6卷 第4期 Diabetes World, Apr 2012,Vol 6, No.4 doi:10.3969/j.issn.1672-7851.2012.04.011 临床综述 GLP-1...
现将 GLP-1 与细 胞凋亡的研究进展综述如下。 钟成福养的乳鼠心肌细胞中研究发现, 与未 经过 GLP-1 预处理组相比 ,经过 GLP-1 预处理的缺氧 / 复氧心肌...
糖依赖 性胰岛索释放肽(glucose-dependentinsulinotropicpolypeptide, 文从基础和临床角度系统阐述GLP-1对糖尿病治疗的分子机 制,并对利拉鲁肽的临床研究结果进行综述。...
http://www.pharmadl.com 上海医药工业研究院信息中心 GLP-1 类似物新药临床疗效综述(二) 类似物新药临床疗效综述((Exenatide+ Liraglutide) )细胞功能——预防并...
( DPP -? ) 抑制剂的研究进展进 行了 * 综述 。 介绍了 G LP -1 的血糖调控机制 , 还对 GLP -1 受体激动剂 ( 如 Ex endin-4 , Exentide LAR, ...
GLP-1)具有强力的促胰岛素分泌作用,将成为2型糖尿病治疗的新方法,是目前胃肠道激素研究的一个新热点,现就GLP-1生化、生理及病理生理学等方面的研究进展综述如下...
2011-10-9胆汁酸的综述_医药卫生_专业资料。关于胆汁酸与血糖、血脂及能量代谢...细胞,这些细胞以 tgr5 依赖性的方式 来分泌肠源性的肠促胰岛素 GLP-1 的...
CRP综述1-2_医药卫生_专业资料。CRP综述一、CRP 综述 C-反应蛋白(CRP)是 1930 年由 Tillet 和 Francis 首先发现的,因为它能与肺炎链球菌荚膜 C 多 糖物质在...
热门文档